Can isotretinoin cause gynaecomastia? This is a question increasingly raised by male patients prescribed isotretinoin for severe acne in the UK. Isotretinoin — available as Roaccutane and several generics — is a highly effective retinoid, but its potential hormonal effects are not fully characterised. Whilst gynaecomastia does not appear as a recognised adverse effect in current UK prescribing information, a small number of case reports have described breast tissue changes in male patients during treatment. This article examines the evidence, identifies who may be at risk, and explains what to do if you notice breast changes whilst taking isotretinoin.

What Is Gynaecomastia and How Does It Develop?

Gynaecomastia is benign glandular breast tissue enlargement in males, caused by an imbalance between oestrogen stimulation and androgen suppression in breast tissue. It can be triggered by hormonal changes, medications, or underlying health conditions.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males. Clinically, it typically presents as a firm or rubbery disc of tissue directly beneath the nipple, which may be tender or mildly painful. It is distinct from pseudogynaecomastia, which involves diffuse fatty tissue accumulation without true glandular growth — a distinction that matters both clinically and when considering causes. The condition can affect one or both breasts.

The underlying mechanism typically involves an imbalance between oestrogen and androgen activity in breast tissue. Oestrogens stimulate glandular proliferation, whilst androgens — particularly testosterone — counteract this effect. When this balance is disrupted, whether through hormonal changes, medications, or underlying health conditions, breast tissue may begin to develop.

Gynaecomastia is relatively common across different life stages:

• Neonatal gynaecomastia occurs due to maternal oestrogen exposure

• Pubertal gynaecomastia affects up to 60% of adolescent males and usually resolves spontaneously within one to two years

• Adult-onset gynaecomastia may be linked to ageing, obesity, liver disease, hypogonadism, or medication use

Obesity can cause both pseudogynaecomastia and true gynaecomastia (via peripheral conversion of androgens to oestrogens), and the two may coexist. A range of medicines are known to cause or contribute to gynaecomastia, including anabolic steroids, anti-androgens, some antipsychotics, and certain cardiovascular drugs. Understanding whether isotretinoin — sometimes referred to by the former brand name Accutane, which is not available in the UK — belongs to this category requires a closer look at its hormonal effects and the available clinical evidence. In the UK, isotretinoin is available as Roaccutane and several generic preparations.

Isotretinoin and Its Effects on Hormones

Isotretinoin is a retinoid that primarily targets sebaceous glands and keratinocytes; it may modestly reduce adrenal androgens such as DHEAS in some patients, but is not classified as an anti-androgen and its endocrine effects remain poorly characterised.

Isotretinoin is a retinoid — a derivative of vitamin A — used primarily in the treatment of severe or treatment-resistant acne. In the UK, it is available as Roaccutane and a number of generic formulations. In accordance with MHRA guidance and NICE NG198 (Acne vulgaris: management), isotretinoin must be prescribed by, or under the direct supervision of, a consultant dermatologist. All patients are required to be enrolled in the Pregnancy Prevention Programme (PPP) before treatment begins, regardless of sex, owing to the drug's teratogenic potential.

Isotretinoin works by targeting multiple pathways involved in acne pathogenesis:

• Reducing sebaceous gland size and sebum production

• Inhibiting keratinocyte proliferation and promoting differentiation

• Decreasing colonisation by Cutibacterium acnes

• Exerting anti-inflammatory effects

Isotretinoin's influence on the endocrine system is less well characterised. Retinoids interact with nuclear receptors — including retinoic acid receptors (RARs) and retinoid X receptors (RXRs) — which can influence gene expression in tissues sensitive to sex hormones. Some studies have suggested that isotretinoin may modestly reduce levels of dehydroepiandrosterone sulphate (DHEAS) and other adrenal androgens in certain patients, though findings across studies are inconsistent and the clinical significance remains unclear.

A relative reduction in androgenic activity, even if subtle, could theoretically shift the oestrogen-to-androgen ratio in breast tissue. However, isotretinoin is not classified as an anti-androgen, and any hormonal effects are considered secondary to its primary mechanism of action. Clinicians and patients should be aware that these endocrine observations are based on limited and heterogeneous data; they do not constitute evidence of a clinically meaningful anti-androgenic effect. The UK Summary of Product Characteristics (SmPC) for isotretinoin preparations, available via the electronic Medicines Compendium (emc), should be consulted for the most current and authoritative information on recognised effects and safety measures.

Evidence Linking Isotretinoin to Gynaecomastia

There is no officially established link between isotretinoin and gynaecomastia; a small number of case reports exist but cannot confirm causality, and no robust signal has been identified in MHRA communications or UK prescribing information.

The question of whether isotretinoin can directly cause gynaecomastia is not definitively answered by current evidence. Gynaecomastia does not appear as a recognised adverse effect in the UK SmPCs for isotretinoin preparations currently listed on the emc, though readers are encouraged to check the most up-to-date SmPC for the specific product prescribed, as wording can vary between marketing authorisation holders. No robust signal for this association has been identified in publicly available MHRA communications or Drug Safety Updates.

Nevertheless, a small number of case reports in the peer-reviewed medical literature have described the development of gynaecomastia in male patients during or shortly after a course of isotretinoin. These reports are notable but must be interpreted cautiously. Case reports represent the lowest tier of clinical evidence and cannot establish causality. The temporal association between isotretinoin use and breast tissue changes does not confirm that the drug was responsible, particularly given that:

• Acne commonly affects adolescent males, who are already at risk of pubertal gynaecomastia

• Other concurrent factors — including weight changes, hormonal fluctuations, recreational drug use (e.g., cannabis, anabolic agents), or other medications — may contribute

• Spontaneous resolution of gynaecomastia is common in younger males regardless of treatment

To date, there are no large-scale controlled studies that conclusively establish isotretinoin as a causative agent for gynaecomastia. In summary, there is no officially established link between isotretinoin and gynaecomastia, though isolated case reports exist and cannot be entirely dismissed. Patients and clinicians should maintain appropriate vigilance without overstating the risk.

How Common Is This Side Effect and Who Is at Risk?

Gynaecomastia during isotretinoin treatment appears exceptionally rare and is not listed in official prescribing information; adolescent males, those with hormonal imbalances, and patients taking concurrent medications are at greatest overlapping risk.

Given the absence of gynaecomastia from the official prescribing information for isotretinoin, it is not possible to quote a reliable incidence figure. Based on the limited case report data available, any association — if real — would appear to be rare. Isotretinoin is prescribed widely in specialist dermatology settings across the UK, and reports of gynaecomastia remain exceptionally infrequent in the published literature.

Certain groups may theoretically be at greater risk of developing gynaecomastia during isotretinoin treatment, not necessarily because of the drug itself, but due to overlapping risk factors:

• Adolescent males (aged 13–19): This group is already predisposed to pubertal gynaecomastia, making it difficult to attribute breast changes solely to isotretinoin

• Individuals with pre-existing hormonal imbalances: Conditions such as hypogonadism or elevated oestrogen levels may increase susceptibility

• Those taking concurrent medications or substances: Some drugs, supplements, anabolic agents, cannabis, and alcohol may independently contribute to gynaecomastia

• Patients with liver impairment: The liver plays a key role in sex hormone metabolism; impaired function can alter oestrogen clearance

• Individuals with obesity: Excess adipose tissue promotes peripheral conversion of androgens to oestrogens and may cause or worsen both pseudogynaecomastia and true gynaecomastia

Patients and clinicians should remain alert to breast changes during treatment without assuming they are drug-related. A thorough review of all concurrent medications, supplements, and lifestyle factors is important when evaluating any new breast change.

What to Do If You Notice Breast Tissue Changes on Isotretinoin

Report any breast swelling, tenderness, or lump to your prescribing dermatologist or GP promptly without stopping isotretinoin unilaterally; urgent assessment is needed if red-flag features such as a hard lump, nipple discharge, or testicular mass are present.

If you are taking isotretinoin and notice swelling, tenderness, or a lump beneath one or both nipples, it is important to remain calm but equally not to ignore the change. Whilst the likelihood of isotretinoin being the direct cause is low, any new breast tissue change in a male patient warrants proper clinical assessment.

Steps to take if you notice breast changes:

• Seek prompt advice from your prescribing dermatologist or GP — do not stop isotretinoin without speaking to them first, as stopping may or may not be recommended depending on the clinical assessment; this decision should be made with your specialist

• Document when the change appeared — note whether it coincided with starting isotretinoin, a dose change, or another event

• Review all medications and substances — consider whether you have started any new supplements, protein powders, recreational drugs (including cannabis or anabolic agents), or other medicines, as some contain compounds that affect hormone levels

• Book an appointment with your GP promptly, particularly if the swelling is painful, rapidly enlarging, hard or irregular, associated with skin dimpling, nipple inversion, nipple discharge, or swollen lymph nodes in the armpit — these are red-flag features requiring urgent assessment

Your GP will take a thorough history, examine both breasts and the testes, and may arrange blood tests including testosterone, oestradiol, luteinising hormone (LH), follicle-stimulating hormone (FSH), prolactin, serum beta-hCG (to exclude a testicular germ cell tumour), and thyroid function tests. Liver function tests may also be requested.

In most cases, gynaecomastia in younger males is benign and self-limiting. However, it is important to exclude underlying conditions such as testicular tumours, which can present with gynaecomastia due to excess oestrogen or hCG production. In line with NICE NG12 (Suspected cancer: recognition and referral), urgent referral to a breast clinic or urology should be arranged if malignancy cannot be excluded clinically, or if a testicular mass is identified.

Speaking to Your GP or Dermatologist About Your Concerns

Discuss any breast changes openly with your dermatologist or GP, bringing a full medication list; suspected adverse reactions should be reported via the MHRA Yellow Card scheme, and discontinuation of isotretinoin should only be decided with specialist input.

Experiencing these side effects? Our pharmacists can help you navigate them →

Open communication with your healthcare team is essential when taking a medication as potent as isotretinoin. In the UK, isotretinoin must be prescribed by or under the direct supervision of a consultant dermatologist, and all patients are enrolled in the Pregnancy Prevention Programme (PPP) for the duration of treatment. If you are concerned about gynaecomastia or any other side effect, your dermatologist or GP is best placed to assess your individual situation and provide personalised advice.

When attending your appointment, it may be helpful to:

• Bring a list of all current medications and supplements, including over-the-counter products, herbal remedies, and any recreational substances

• Describe the breast changes clearly — location, duration, whether one or both sides are affected, and any associated symptoms such as pain, discharge, or skin changes

• Ask about the benefit-risk balance of continuing isotretinoin, particularly if you are mid-course and responding well to treatment

Your dermatologist may choose to continue isotretinoin if the breast changes are mild and likely attributable to puberty or another identifiable cause. Alternatively, they may recommend a dose reduction, temporary pause, or cessation whilst investigations are completed — this will depend on the clinical picture.

Regarding prognosis, many cases of drug-associated gynaecomastia improve gradually over several months after the causative agent is withdrawn. However, resolution is not guaranteed, particularly if the changes have been present for more than 12 months, in which case referral to an endocrinologist or breast surgeon may be appropriate for further management.

Any suspected adverse drug reaction to isotretinoin should be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk), which helps regulators monitor the safety of medicines in real-world use. The British Association of Dermatologists (BAD) also provides patient information on isotretinoin that may be a useful reference.

It is worth emphasising that isotretinoin remains one of the most effective treatments available for severe acne, and the decision to discontinue should not be taken lightly. Most patients complete their course without experiencing hormonal side effects. Ongoing follow-up with your specialist team ensures that any changes are monitored appropriately and that your overall health is protected throughout treatment.

Frequently Asked Questions